Mankind Pharma appoints Story Digital as integrated creative agency for HealthOK
NiveshIQ
NSE: MANKIND · Pharma
Mankind Pharma Ltd.
₹2,280.00▲ ₹41.60 (+1.86%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MANKIND. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Mankind Pharma Ltd.
Mankind Pharma Limited is a leading developer, manufacturer, and marketer of pharmaceutical formulations and consumer healthcare products in India and internationally, with a diverse portfolio of products across therapeutic areas such as anti-infective, cardiovascular, and gastrointestinal, among others. The company's key revenue drivers include its pharmaceutical formulations business, which accounts for the majority of its revenue, as well as its consumer healthcare products, including condoms, pregnancy detection kits, and vitamin supplements. Recently, Mankind Pharma reported a 13% increase in Q1 revenue to ₹4,030 crore, driven by strong growth in its pharmaceutical formulations business. The company has also been expanding its global presence, with the incorporation of a wholly-owned
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10,260 Cr +15.60% | ₹12,207 Cr +19.00% | ₹14,278 Cr +17.00% |
| EBITDA Margin | 24.53% | 24.79% | 27.85% |
| Net Profit | ₹1,942 Cr +48.30% | ₹2,011 Cr +3.60% | ₹2,056 Cr +2.20% |
| EPS | ₹47.75 | ₹48.26 | ₹46.35 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Mankind Pharma to absorb Bharat Serums’ business through voluntary liquidation, bypassing NCLT merger route
Mankind Pharma to attend three investor conferences in September 2026
🔒
+ 3 more stories about Mankind Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹4, 031 Cr, PAT ₹574 Cr, EPS ₹13.76, EBITDA margin 27.3%. Growth context: revenue QoQ +17.1%, PAT QoQ -0.9%. Street verdict: inline, revenue surprise +1.6%, PAT surprise +2.2%.
Key drivers for the stock over the next 2–4 quarters will be patient volumes, occupancy, ARPOB/ARPO, case mix, and bed-c...
In FY26, Mankind reported revenue of ₹14, 278 Cr, PAT of ₹2, 056 Cr, an EBITDA margin of 27.9%, and EPS of ₹46.35, repre...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MANKIND
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MANKIND alongside your other holdings
Unlock full MANKIND research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Mankind Pharma Ltd.?
NiveshIQ detects active intelligence signals for Mankind Pharma Ltd. (MANKIND) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Mankind Pharma Ltd.?
Mankind Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹10,002,830.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.